|

recombinant human endostatin,temozolomide,irinotecan Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Beijing Sanbo Brain Hospital1

Indications

  • Lower Grade Glioma, Recurrent1
  • Glioblastoma, Recurrent1
  • Cancer1

Other1 trial

Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.